featured
Bendamustine/Rituximab With Bortezomib Induction or Lenalidomide Continuation in Follicular Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab With Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Clin. Cancer Res 2020 Jun 12;[EPub Ahead of Print], AM Evens, F Hong, TM Habermann, RH Advani, RD Gascoyne, TE Witzig, A Quon, EA Ranheim, SM Ansell, PS Cheema, PA Dy, TE O'Brien, JN Winter, TP Cescon, JE Chang, B KahlFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.